Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Langeza Saleh is active.

Publication


Featured researches published by Langeza Saleh.


Hypertension | 2015

Association Studies Suggest a Key Role for Endothelin-1 in the Pathogenesis of Preeclampsia and the Accompanying Renin-Angiotensin-Aldosterone System Suppression

Koen Verdonk; Langeza Saleh; Stephanie Lankhorst; J.E. Ilse Smilde; Manon van Ingen; Ingrid M. Garrelds; Edith C. H. Friesema; Henk Russcher; Anton H. van den Meiracker; Willy Visser; A.H. Jan Danser

Women with preeclampsia display low renin–angiotensin–aldosterone system activity and a high antiangiogenic state, the latter characterized by high levels of soluble Fms-like tyrosine kinase (sFlt)-1 and reduced placental growth factor levels. To investigate whether renin–angiotensin–aldosterone system suppression in preeclampsia is because of this disturbed angiogenic balance, we measured mean arterial pressure, creatinine, endothelin-1 (ET-1), and renin–angiotensin–aldosterone system components in pregnant women with a high (≥85; n=38) or low (<85; n=65) soluble Fms-like tyrosine kinase-1/placental growth factor ratio. Plasma ET-1 levels were increased in women with a high ratio, whereas their plasma renin activity and plasma concentrations of renin, angiotensinogen, and aldosterone were decreased. Plasma renin activity–aldosterone relationships were identical in both the groups. Multiple regression analysis revealed that plasma renin concentration correlated independently with mean arterial pressure and plasma ET-1. Plasma ET-1 correlated positively with soluble Fms-like tyrosine kinase-1 and negatively with plasma renin concentration, and urinary protein correlated with plasma ET-1 and mean arterial pressure. Despite the lower plasma levels of renin and angiotensinogen in the high-ratio group, their urinary levels of these components were elevated. Correction for albumin revealed that this was because of increased glomerular filtration. Subcutaneous arteries obtained from patients with preeclampsia displayed an enhanced, AT2 receptor-mediated response to angiotensin II. In conclusion, a high antiangiogenic state associates with ET-1 activation, which together with the increased mean arterial pressure may underlie the parallel reductions in renin and aldosterone in preeclampsia. Because ET-1 also was a major determinant of urinary protein, our data reveal a key role for ET-1 in the pathogenesis of preeclampsia. Finally, the enhanced angiotensin responsiveness in preeclampsia involves constrictor AT2 receptors.


Therapeutic Advances in Cardiovascular Disease | 2016

The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Langeza Saleh; Koen Verdonk; Willy Visser; Anton H. van den Meiracker; A.H. Jan Danser

Pre-eclampsia (PE) is the most frequently encountered medical complication during pregnancy. It is characterized by a rise in systemic vascular resistance with a relatively low cardiac output and hypovolemia, combined with severe proteinuria. Despite the hypovolemia, renin–angiotensin system (RAS) activity is suppressed and aldosterone levels are decreased to the same degree as renin. This suggests that the RAS is not the cause of the hypertension in PE, but rather that its suppression is the consequence of the rise in blood pressure. Abnormal placentation early in pregnancy is widely assumed to be an important initial event in the onset of PE. Eventually, this results in the release of anti-angiogenic factors [in particular, soluble Fms-like tyrosine kinase-1 (sFlt-1)] and cytokines, leading to generalized vascular dysfunction. Elevated sFlt-1 levels bind and inactivate vascular endothelial growth factor (VEGF). Of interest, VEGF inhibition with drugs like sunitinib, applied in cancer patients, results in a PE-like syndrome, characterized by hypertension, proteinuria and renal toxicity. Both in cancer patients treated with sunitinib and in pregnant women with PE, significant rises in endothelin-1 occur. Multiple regression analysis revealed that endothelin-1 is an independent determinant of the hypertension and proteinuria in PE, and additionally a renin suppressor. Moreover, studies in animal models representative of PE, have shown that endothelin receptor blockers prevent the development of this disease. Similarly, endothelin receptor blockers are protective during sunitinib treatment. Taken together, activation of the endothelin system emerges as an important pathway causing the clinical manifestations of PE. This paper critically addresses this concept, taking into consideration both clinical and preclinical data, and simultaneously discusses the therapeutic consequences of this observation.


Current Opinion in Pharmacology | 2015

Etiology of angiogenesis inhibition-related hypertension

Stephanie Lankhorst; Langeza Saleh; A.H. Jan Danser; Anton H. van den Meiracker

Angiogenesis inhibition, targeting vascular endothelial growth factor (VEGF) or its receptors, is an established treatment for solid tumors. A common side effect of this treatment is the development of sometimes severe hypertension. This hypertension is associated with a decrease in nitric oxide production, activation of the endothelin-signaling pathway and renin suppression. The mechanism underlying activation of the endothelin-signaling pathway is not fully understood. Both activation of endothelial cells and disinhibition of the VEGF-induced suppression of endothelin production by endothelial cells may be involved. The development of hypertension can be a reason to discontinue the angiogenesis inhibitor, thereby compromising anticancer treatment, but possibly is also a biomarker for a favorable antitumor response.


European Journal of Obstetrics & Gynecology and Reproductive Biology | 2016

The sFlt-1/PlGF ratio associates with prolongation and adverse outcome of pregnancy in women with (suspected) preeclampsia: analysis of a high-risk cohort.

Langeza Saleh; Koen Verdonk; A.H. Jan Danser; Eric A.P. Steegers; Henk Russcher; Anton H. van den Meiracker; Willy Visser

OBJECTIVE To evaluate the additive value of the sFlt-1/PlGF ratio for diagnosing preeclampsia (PE) and predicting prolongation of pregnancy and adverse outcome in a cohort of women with PE or at high risk of PE. STUDY DESIGN Patients with suspected or confirmed clinical PE were recruited. At time of inclusion blood for measurement of sFlt-1and PlGF was taken. Values were determined after delivery. A cut-off ratio of ≥85 was defined as a positive test. RESULTS A total of 107 patients were included. Of the patients, 62 (58%) met the clinical criteria of PE at time of blood sampling. In 10% of these patients (n=6) the ratio was <85 (false negative), whereas in 7% (n=3) of patients without clinical PE the ratio was ≥85 (false positive), resulting in positive and negative predictive values of 95% and 88% respectively. One patient with false positive ratio developed superimposed PE and 2 developed gestational hypertension, and adverse outcome occurred in all three. An adverse pregnancy outcome was only encountered in 1 of the 6 patients with a false negative ratio. Using a binary regression model with adjustment for gestational age <34 weeks, the adverse outcome risk was 11 times increased on the basis of clinical PE, and 30 times on the basis of an elevated ratio (P=0.036). CONCLUSION The additive value of an increased ratio for diagnosing PE is limited since most patients with clinical PE also have a positive ratio. However, an elevated ratio is superior to the clinical diagnosis of PE for predicting an adverse pregnancy outcome. Furthermore, irrespective of clinical PE, a low ratio is inversely correlated with prolongation of pregnancy.


Current Opinion in Nephrology and Hypertension | 2016

Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment.

Langeza Saleh; Jan Danser; Anton H. van den Meiracker

Purpose of reviewPreeclampsia is a systemic, pregnancy-related disorder featuring hypertension and proteinuria arising from placental overproduction of soluble FMS-like tyrosine kinase-1, resulting in an antiangiogenic state because of the inhibition of the vascular endothelial growth factor (VEGF) family. Similarly, antiangiogenetic treatment aimed at targeting VEGF in patients with cancer is associated with a preeclampsia-like syndrome. In this study we discuss the pathophysiological role of an activated endothelin system in both conditions. Recent findingsIn different experimental forms of preeclampsia, in clinical preeclampsia, and in cancer patients on antiangiogenic treatment, activation of the endothelin axis invariably occurs and this activation is directly related to the circulating level of sFlt-1 or the intensity of antiangiogenic treatment. Administration of endothelin receptor A-selective or dual endothelin receptor antagonists can prevent or largely attenuate the hypertension and proteinuria in experimental forms of preeclampsia, as well as in rats exposed to receptor tyrosine-kinase inhibitors targeting VEGF-signaling, supporting the concept that activation of the endothelin axis plays a key role in the manifestations of these disorders. SummaryActivation of the endothelin axis has now emerged as a crucial player in the manifestations of preeclampsia and following antiangiogenic treatment. As a consequence, blockade of the endothelin system may be considered as a treatment option both in preeclampsia and in antiangiogenesis-induced hypertension and renal toxicity in patients with cancer.


Hypertension | 2017

Angiogenic Markers Predict Pregnancy Complications and Prolongation in Preeclampsia: Continuous Versus Cutoff Values

Langeza Saleh; Yvonne Vergouwe; Anton H. van den Meiracker; Koen Verdonk; Henk Russcher; Henk A. Bremer; Hans Versendaal; Eric A.P. Steegers; A.H. Jan Danser; Willy Visser

To assess the incremental value of a single determination of the serum levels of sFlt-1 (soluble Fms-like tyrosine kinase 1) and PlGF (placental growth factor) or their ratio, without using cutoff values, for the prediction of maternal and fetal/neonatal complications and pregnancy prolongation, 620 women with suspected/confirmed preeclampsia, aged 18 to 48 years, were included in a prospective, multicenter, observational cohort study. Women had singleton pregnancies and a median pregnancy duration of 34 (range, 20–41) weeks. Complications occurred in 118 women and 248 fetuses. The median duration between admission and delivery was 12 days. To predict prolongation, PlGF showed the highest incremental value (R2=0.72) on top of traditional predictors (gestational age at inclusion, diastolic blood pressure, proteinuria, creatinine, uric acid, alanine transaminase, lactate dehydrogenase, and platelets) compared with R2=0.53 for the traditional predictors only. sFlt-1 showed the highest value to discriminate women with and without maternal complications (C-index=0.83 versus 0.72 for the traditional predictors only), and the sFlt-1/PlGF ratio showed the highest value to discriminate fetal/neonatal complications (C-index=0.86 versus 0.78 for the traditional predictors only). Applying previously suggested cutoff values for the sFlt-1/PlGF ratio yielded lower incremental values than applying continuous values. In conclusion, sFlt-1 and PlGF are strong and independent predictors for days until delivery along with maternal and fetal/neonatal complications on top of the traditional criteria. Their use as continuous variables (instead of applying cutoff values for different gestational ages) should now be tested in a prospective manner, making use of an algorithm calculating the risk of an individual woman with suspected/confirmed preeclampsia to develop complications.


Hypertension | 2017

Low Soluble Fms-Like Tyrosine Kinase-1, Endoglin, and Endothelin-1 Levels in Women With Confirmed or Suspected Preeclampsia Using Proton Pump InhibitorsNovelty and Significance

Langeza Saleh; Raaho Samantar; Ingrid M. Garrelds; Anton H. van den Meiracker; Willy Visser; A.H. Jan Danser

Patients with preeclampsia display elevated placenta-derived sFlt-1 (soluble Fms-like tyrosine kinase-1) and endoglin levels and decreased placental growth factor levels. Proton pump inhibitors (PPIs) decrease trophoblast sFlt-1 and endoglin secretion in vitro. PPIs are used during pregnancy to combat reflux disease. Here, we investigated whether PPIs affect sFlt-1 in women with confirmed/suspected preeclampsia, making use of a prospective cohort study involving 430 women. Of these women, 40 took PPIs (6 esomeprazole, 32 omeprazole, and 2 pantoprazole) for 8 to 45 (median 29) days before sFlt-1 measurement. Measurements were only made once, at study entry between weeks 20 and 41 (median 33 weeks). PPI use was associated with lower sFlt-1 levels, with no change in placental growth factor levels, both when compared with all non-PPI users and with 80 gestational age-matched controls selected from the non-PPI users. No sFlt-1/placental growth factor alterations were observed in women using ferrous fumarate or macrogol while, as expected, women using antihypertensive medication displayed higher sFlt-1 levels and lower placental growth factor levels. The PPI use-associated decrease in sFlt-1 was independent of the application of antihypertensive drugs and also occurred when restricting our analysis to patients with hypertensive disease of pregnancy at study entry. PPI users displayed more cases with preexisting proteinuria, less gestational hypertension, and a lower number of neonatal sepsis cases. Finally, their plasma endoglin and endothelin-1 levels were lower while sFlt-1 levels correlated positively with both. In conclusion, PPI use associates with low sFlt-1, endoglin, and endothelin-1 levels, warranting prospective trials to investigate the therapeutic potential of PPIs in preeclampsia.


Ultrasound in Obstetrics & Gynecology | 2018

Soluble fms‐like tyrosine kinase‐1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre‐eclampsia

Langeza Saleh; A. H. Van Den Meiracker; R. Geensen; Aslihan Kaya; J.E. Roeters van Lennep; Johannes J. Duvekot; Koen Verdonk; E.A.P. Steegers; Henk Russcher; A.H.J. Danser; Willy Visser

To assess the evolution of the soluble fms‐like tyrosine kinase‐1 (sFlt‐1) to placental growth factor (PlGF) ratio in women with suspected or confirmed pre‐eclampsia (PE), and to investigate the changes in sFlt‐1 and PlGF levels in pre‐eclamptic women after delivery.Objectives To assess the evolution of the sFlt-1/PlGF ratio in women with suspected or with confirmed preeclampsia and to investigate the changes in sFlt-1 and PlGF levels in preeclamptic women after delivery. Methods In this exploratory tertiary referral university centre study, using the Roche Diagnostics Elecsys assay, sFlt-1 and PlGF were determined in two groups of patients. In the first group of 46 patients with suspected or confirmed preeclampsia, sFlt-1 and PlGF were measured at least twice during their pregnancy. Women had singleton pregnancies and a median pregnancy duration of 26 weeks (range 18 – 40 weeks). In the second group, sFlt-1 and PlGF of 26 preeclamptic patients were determined before and after delivery. The median gestational age at inclusion was 29 weeks (16 – 37) and the median days between antepartum measurement and delivery was 2 days (1 – 7). Results In the first group, 90% of patients with a sFlt-1/PlGF ratio ≤38 at baseline (n = 30), ruling out PE, the sFlt-1/PlGF ratio remained stable for up to 100 days. In 16 patients with a sFlt-1/PlGF ratio >38 and in 10% of those with a sFlt-1/PlGF ratio <38 at baseline the ratio increased further. In the second group, after delivery, sFlt-1 dropped to <1% of its pre-delivery values with a half-life of 1.4 ± 0.3 days, while PlGF dropped to ≈ 30% of its pre-delivery values with a half-life of 3.7 ± 4.3 days. Conclusions Based on this small cohort, up to 10% of women admitted with suspected or confirmed PE presenting with a sFlt-1/PlGF ratio ≤38 display a rise of this sFlt-1/PlGF ratio in subsequent weeks, implying that repeated determination of the sFlt-1/PlGF ratio is required to reject this condition definitively. Furthermore, the rapid and pronounced decline of sFlt-1 values after delivery in patients with PE/HELLP suggests that sFlt-1, in contrast with PlGF, is almost entirely placenta-derived.


Ultrasound in Obstetrics & Gynecology | 2017

sFlt-1 and PlGF kinetics during and after pregnancy in women with suspected or confirmed preeclampsia

Langeza Saleh; Anton H. van den Meiracker; Roos Geensen; Aslihan Kaya; Jeanine E. Roeters van Lennep; Johannes J. Duvekot; Koen Verdonk; Eric A.P. Steegers; Henk Russcher; Jan Danser; Willy Visser

To assess the evolution of the soluble fms‐like tyrosine kinase‐1 (sFlt‐1) to placental growth factor (PlGF) ratio in women with suspected or confirmed pre‐eclampsia (PE), and to investigate the changes in sFlt‐1 and PlGF levels in pre‐eclamptic women after delivery.Objectives To assess the evolution of the sFlt-1/PlGF ratio in women with suspected or with confirmed preeclampsia and to investigate the changes in sFlt-1 and PlGF levels in preeclamptic women after delivery. Methods In this exploratory tertiary referral university centre study, using the Roche Diagnostics Elecsys assay, sFlt-1 and PlGF were determined in two groups of patients. In the first group of 46 patients with suspected or confirmed preeclampsia, sFlt-1 and PlGF were measured at least twice during their pregnancy. Women had singleton pregnancies and a median pregnancy duration of 26 weeks (range 18 – 40 weeks). In the second group, sFlt-1 and PlGF of 26 preeclamptic patients were determined before and after delivery. The median gestational age at inclusion was 29 weeks (16 – 37) and the median days between antepartum measurement and delivery was 2 days (1 – 7). Results In the first group, 90% of patients with a sFlt-1/PlGF ratio ≤38 at baseline (n = 30), ruling out PE, the sFlt-1/PlGF ratio remained stable for up to 100 days. In 16 patients with a sFlt-1/PlGF ratio >38 and in 10% of those with a sFlt-1/PlGF ratio <38 at baseline the ratio increased further. In the second group, after delivery, sFlt-1 dropped to <1% of its pre-delivery values with a half-life of 1.4 ± 0.3 days, while PlGF dropped to ≈ 30% of its pre-delivery values with a half-life of 3.7 ± 4.3 days. Conclusions Based on this small cohort, up to 10% of women admitted with suspected or confirmed PE presenting with a sFlt-1/PlGF ratio ≤38 display a rise of this sFlt-1/PlGF ratio in subsequent weeks, implying that repeated determination of the sFlt-1/PlGF ratio is required to reject this condition definitively. Furthermore, the rapid and pronounced decline of sFlt-1 values after delivery in patients with PE/HELLP suggests that sFlt-1, in contrast with PlGF, is almost entirely placenta-derived.


Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health | 2018

The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies

Langeza Saleh; Sarea I.M. Tahitu; A.H. Jan Danser; Anton H. van den Meiracker; Willy Visser

OBJECTIVE A sFlt-1/PlGF ratio of ≤38 has been reported to predict the absence of preeclampsia (PE) in singleton pregnancies. We evaluated whether a sFlt-1/PlGF ratio of ≤38 could be used to predict the absence of PE in twin pregnancies and maternal and fetal/neonatal complications. METHODS This is a secondary analysis of a prospective multicenter cohort study that enrolled women with suspected or confirmed PE with the aim of evaluating the use of the sFlt-1, PlGF and their ratio to predict maternal and fetal/neonatal complications. Twin and singleton pregnancies with clinically suspected or confirmed PE were matched for gestational age and parity. Blood samples were drawn at time of study entry, but serum values of sFlt-1 and PlGF and their ratio were determined postpartum. RESULTS Twenty-one women with twin and 21 with singleton gestations were included at a median gestational age of 30 weeks. At inclusion PE was diagnosed in 13 twin and 15 singleton pregnancies. In comparison to singleton control pregnancies, twin controls had a significantly higher sFlt-1 (6377 vs. 1732 pg/ml, p = 0.008), a higher sFlt-1/PlGF ratio 26 vs. 3 p = 0.361) and a lower PlGF (228 vs. 440 pg/ml p = 0.479). Compared to singleton preeclamptic pregnancies values of sFlt-1 (9134 vs. 8625 pg/ml) did not differ, whereas values of PlGF (185 vs. 33 pg/ml, p < 0.001) were higher and values of the ratio (49 vs. 158, p = 0.002) were lower in preeclamptic twin pregnancies. All preeclamptic patients with a singleton pregnancy had a ratio >38, but only 5 of the 13 patients with a preeclamptic twin pregnancy. Conversely, the ratio was ≤38 in 5 of the 6 control singleton, but in only 4 of the 8 control twin pregnancies. When classified according to a ratio ≤38 or >38 at inclusion, maternal complications occurred more frequently in patients with a ratio >38 both in singleton and twin pregnancies. In singleton pregnancies fetal/neonatal complications, except one admission to NICU, only occurred in patients with a ratio >38. In twin pregnancies fetal/neonatal complications occurred equally frequent in women with a ratio ≤38 or >38. CONCLUSION Serum sFlt-1 levels are considerably higher in twin than in singleton control gestations. A sFlt-1/PlGF ratio of ≤38 to predict short-term absence of PE is not applicable to twin pregnancies in predicting either the absence of PE or the absence of adverse pregnancy outcomes.

Collaboration


Dive into the Langeza Saleh's collaboration.

Top Co-Authors

Avatar

Willy Visser

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Koen Verdonk

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Henk Russcher

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Jan Danser

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

A.H. Jan Danser

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Eric A.P. Steegers

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A.H.J. Danser

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

E.A.P. Steegers

Erasmus University Rotterdam

View shared research outputs
Researchain Logo
Decentralizing Knowledge